Ultimovacs ASA: Notification of major holdings

09 Jan 2025 12:00 CET

Oslo, 9 January 2025: Reference is made to the stock exchange notices published
by Ultimovacs ASA (the "Company") on (i) 17 December 2024 regarding the
contemplated business combination between the Company and Zelluna Immunotherapy
AS (the "Business Combination") and the fully committed private placement with
gross proceeds of approx. NOK 51.7 million (the "Private Placement") and (ii)
today on 9 January 2025 regarding the approval by an extraordinary general
meeting of the Company (the "EGM") of relevant resolutions related to the
Business Combination and the Private Placement. The Business Combination and the
Private Placement are hereinafter referred to as the "Transactions".

Following the EGM's resolutions to approve the issuance of 167,864,598 shares in
aggregate through the Transactions, and subject to completion of the
Transactions, certain of the Company's and Zelluna Immunotherapy AS' major
shareholders will cross threshold for disclosure of shareholdings pursuant to
Chapter 4 of the Norwegian Securities Trading Act as follows:

* Geveran Trading Company Ltd. has been allocated 4,230,769 offer shares in
the Company in the Private Placement and will receive 20,847,543
consideration shares in the Business Combination, increasing its
shareholding from 0 shares and votes to 25,078,312 shares and votes (approx.
12.4%) in the Company after completion of the Transactions.

* Radforsk has been allocated 1,038,461 offer shares in the Company in the
Private Placement and will receive 22,156,490 consideration shares in the
Business Combination, increasing its shareholdings from 1,519,263 shares and
votes (approx. 4.4% as of the date hereof) to 24,714,214 shares and votes
(approx. 12.2%) in the Company after completion of the Transactions.

* Inven2 AS has been allocated 384,615 offer shares in the Company in the
Private Placement and will receive 19,357,583 consideration shares in the
Business Combination, increasing its shareholdings from 1,265,139 shares and
votes (approx. 3.7% as of the date hereof) to 21,007,337 shares and votes
(approx. 10.4%) in the Company after completion of the Transactions.

* Gjelsten Holding AS has been allocated 3,653,846 offer shares in the Company
in the Private Placement and will not receive any consideration shares in
the Business Combination, thus decreasing its total percentage of shares as
a result of the Transactions from 6,495,866 shares and votes (approx.
18.88% as of the date hereof) to 10,149,712 shares and votes (approx. 5.0%)
in the Company after completion of the Transactions.

* Takeda Ventures, Inc. will receive 12,389,348 consideration shares in the
Business Combination, increasing its shareholdings from 0 shares and votes
to 12,389,348 shares and votes (approx. 6.1%) in the Company after
completion of the Transactions.

* Birk Venture AS has been allocated 538,461 offer shares in the Company in
the Private Placement and will receive 14,196,604 consideration shares in
the Business Combination, increasing its shareholdings from 0 shares and
votes to 14,735,065 shares and votes (approx. 7.3%) in the Company after
completion of the Transactions.

This information is subject to the disclosure requirements pursuant to Section
4-2 the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site